Autonomix Medical Secures Canadian Patent for Advanced Neural Sensing in Endoscopic Sympathectomy

Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company specializing in precision nerve-targeted therapies, announced on July 13, 2026, that it has been granted Canadian Patent No. 3,158,197, entitled "Endoscopic Sympathectomy Systems and Methods." This patent adds to the Company’s expanding global intellectual property portfolio, which now comprises 112 issued or pending patent applications worldwide.

The newly issued Canadian patent reinforces Autonomix’s intellectual property estate related to real-time nerve sensing, mapping, physiological monitoring, and feedback-guided neuromodulation technologies. These patented systems and methods aim to enable more precise targeting of autonomic nerves implicated in a range of chronic diseases, including hypertension, chronic heart failure, chronic renal failure, metabolic disorders, and other conditions linked to autonomic nervous system dysfunction and renal sympathetic nerve hyperactivity.

Unlike traditional denervation techniques that primarily depend on anatomical landmarks, the patented technology integrates sensing-enabled devices capable of detecting neural and physiological responses in real time. This closed-loop approach allows physicians to accurately locate neural targets, assess treatment effects during therapy delivery, and evaluate procedural success using objective physiological feedback.

Autonomix’s portfolio includes corresponding patents previously issued in the United States and Europe, underscoring the Company’s robust intellectual property position across major commercial markets.

Brad Hauser, Chief Executive Officer of Autonomix, stated, "Securing this Canadian patent further strengthens our competitive position and expands the intellectual property foundation supporting our precision neuromodulation platform. We believe the ability to identify, monitor and modulate neural targets using real-time physiological feedback may represent a transformational advancement in nerve-targeted therapy. This patent not only reinforces our technological differentiation but also supports our vision of expanding the platform across multiple large clinical markets where improved treatment precision may lead to better patient outcomes."

The patent covers systems and methods designed to identify, monitor, and modulate autonomic nerves using minimally invasive tools capable of sensing physiological and electrophysiological activity before, during, and after treatment. Key covered technologies include:

- Real-time monitoring of electrophysiological activity near organs and blood vessels;

- Nerve sensing and mapping technologies for identifying and characterizing autonomic neural targets;

- Closed-loop neuromodulation and denervation systems incorporating procedural feedback;

- Microelectrode- and microsensor-based surgical tools capable of sensing and stimulating tissue;

- Methods for evaluating the effectiveness of neuromodulation procedures through physiological monitoring.

Autonomix has developed a comprehensive intellectual property portfolio that provides broad, area-specific protection across the body. This portfolio encompasses core platforms for nerve sensing, nerve mapping, signal processing, and controlled micro-ablation, alongside application-specific innovations for multiple organ systems. With issued patents in the United States and key international jurisdictions, and patent expirations extending into the late 2030s, the portfolio is structured to support scalability and expansion into diverse clinical indications.

The Company’s first-in-class platform technology features a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than currently available technologies. This capability aims to enable transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

Autonomix is initially developing this technology for pain treatment, focusing on pancreatic cancer—a condition characterized by debilitating pain and lacking reliable solutions. The platform holds potential for addressing numerous indications, including cardiology, hypertension, and chronic pain management across a broad disease spectrum. The technology remains investigational and has not yet received marketing clearance in the United States.

Autonomix encourages interested parties to visit autonomix.com and connect with the Company on social media platforms including X, LinkedIn, Instagram, and Facebook for further information.

The Company also issued a cautionary statement noting that certain statements in the release are forward-looking and subject to risks and uncertainties. These include expectations regarding the intellectual property portfolio’s scope and competitive value, the clinical benefits of nerve-targeted treatments, planned clinical studies, physician adoption, strategic partnerships, and reimbursement discussions. Actual results may differ materially from these forward-looking statements. Investors are advised to review the Company’s filings with the U.S. Securities and Exchange Commission, including the Annual Report on Form 10-K filed on May 27, 2026.